In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.
Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.
We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study
Am 4. November 2022 veranstalten GBG und IKF ihr 1. Herbst-Symposium in Frankfurt/Main.
Das 20. GBG-Jahrestreffen findet vom 2.-3. März 2023 in Frankfurt statt.
We are very excited to announce that the next 18th St.Gallen International Breast Cancer Conference 2023 will take place from 15 – 18 March 2023 in Vienna/ Austria.
Mit fast 30 TeilnehmerInnen war die GBG beim diesjährigen Race for Survival in Frankfurt.
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
We are proud to present our research at ESMO Congress 2022 in Paris.
We are pleased to inform you that a subanalysis of HER2-positive breast cancer patients with brain metastasis from the BMBC registry has been published in ESMO Open.
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
We are pleased to inform you that outcome of pregnant breast cancer patients treated with chemotherapy versus non-pregnant controls has been published in European Journal of Cancer
Bitte beachten Sie unsere neue Anschrift ab dem 18. Juli 2022.
We are pleased to inform you that primary results from GeparX trial have been published in JAMA Oncology.
In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.
Neue Daten zum Überleben von Brustkrebspatientinnen mit Chemotherapie während der Schwangerschaft
We are happy to present our research at the ASCO Annual meeting June 2022.
We are pleased to inform you that a STEPP analysis of the updated data from the APHINITY trial has been published in European Journal of Cancer
GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.